A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
Zhenfeng Duan(Harvard University Press), Francis J. Hornicek(Massachusetts General Hospital)
Cited by 33
Related Papers
Novel strategies to prevent the development of multidrug resistance (MDR) in cancer
|Oncotarget|2017|208
Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
|BMC Cancer|2009|161
MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer
|Scientific Reports|2015|156